Company Profile

Avrygen Corporation
Profile last edited on: 10/26/2016      CAGE: 5AY63      UEI: EDYLS6D8L1B7

Business Identifier: Gene-based therapeutics for bone and muscle diseases
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

475 Brannan Street Suite 220
San Francisco, CA 94107
   (415) 640-1917
Location: Single
Congr. District: 12
County: San Francisco

Public Profile

Avrygen Corporation is a development stage biotechnology company with a proprietary gene therapy technology. Avrygen is developing therapeutic biological drugs for bone and muscle diseases such as osteoarthritis, rheumatoid arthritis, osteoporosis, muscle wasting, and macular degeneration. The company's NanoKorĀ® platform technology is aimed at overcoming many of the shortcomings of current nucleotide delivery formulations. ??

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2014 1 NIH $224,980
Project Title: Dual Targeted Nanoparticle Therapy For Glioblastoma Multiforme
2013 1 CBD $99,999
Project Title: Novel physiological depot formulations for long-term butyrylcholinesterase delivery
2012 1 Army $100,000
Project Title: Therapy for Secondary Lymphedema

Key People / Management

  Randal S Goomer -- President

Company News

There are no news available.